(KURA) Kura Oncology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US50127T1097

Ziftomenib, Tipifarnib, KO-2806

Stock: Biotechnology
Age 10.3y
MCap 775m
Avg Vol 1.46M (13.8M USD)
Beta 0.963
Volatility 57.14%

EPS (Earnings per Share)

EPS (Earnings per Share) of KURA over the last years for every Quarter: "2020-12": -0.45, "2021-03": -0.46, "2021-06": -0.51, "2021-09": -0.5, "2021-12": -0.49, "2022-03": -0.49, "2022-06": -0.52, "2022-09": -0.53, "2022-12": -0.49, "2023-03": -0.5, "2023-06": -0.53, "2023-09": -0.5, "2023-12": -0.55, "2024-03": -0.59, "2024-06": -0.59, "2024-09": -0.63, "2024-12": -0.22, "2025-03": -0.66, "2025-06": -0.75, "2025-09": -0.85, "2025-12": 0,
EPS CAGR: 23.20%
EPS Trend: 5.2%
Last SUE: 1.21
Qual. Beats: 1

Revenue

Revenue of KURA over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 1.27, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 53.883, 2025-03: 14.108, 2025-06: 15.288, 2025-09: 20.75, 2025-12: null,
Rev. CAGR: 52.37%
Rev. Trend: 74.3%
Last SUE: -1.39
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 57.1%
Value at Risk 5%th 84.6%
Relative Tail Risk -9.97%
Reward TTM
Sharpe Ratio 0.51
Alpha -0.68
CAGR/Max DD -0.20
Character TTM
Hurst Exponent 0.404
Beta 0.963
Beta Downside 0.743
Drawdowns 3y
Max DD 76.46%
Mean DD 36.82%
Median DD 30.07%

Description: KURA Kura Oncology December 26, 2025

Kura Oncology Inc. (NASDAQ:KURA) is a clinical-stage biopharma focused on targeted cancer therapies. Its pipeline centers on three investigational agents: ziftomenib, a selective menin-KMT2A inhibitor aimed at genetically defined acute leukemias (AML and ALL); tipifarnib, an oral farnesyl-transferase inhibitor being tested in combination with alpelisib for PIK3CA-driven head-and-neck squamous cell carcinoma (HNSCC); and KO-2806, another farnesyl-transferase inhibitor paired with Mirati’s KRAS G12C blocker adagrasib in non-small-cell lung cancer (NSCLC). The company leverages collaborations with Novartis (tipifarnib + alpelisib), Kyowa Kirin (menin inhibitor development and commercialization) and Mirati (KO-2806 + adagrasib). Headquarters are in San Diego, California.

As of the most recent 10-Q (Q2 2025), Kura reported cash and cash equivalents of roughly $150 million, giving it an estimated 12-month runway at current burn (~$12 million per month). R&D expense accelerated to $38 million year-to-date, reflecting the initiation of Phase 2 trials for ziftomenib and the tipifarnib-alpelisib combination. The biotech sector’s funding environment remains supportive, with venture capital raising up ≈ 15 % YoY in 2024, while FDA’s “oncology priority review” pathway has shortened approval timelines for novel mechanisms of action, a macro-driver that could benefit Kura’s menin-targeted approach.

For a deeper quantitative assessment, see the ValueRay page on KURA.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-216.9m TTM) > 0 and > 6% of Revenue (6% = 6.24m TTM)
FCFTA 0.13 (>2.0%) and ΔFCFTA 48.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 480.0% (prev 33.3k%; Δ -32.8kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.14 (>3.0%) and CFO 87.8m > Net Income -216.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 5.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (87.6m) change vs 12m ago 0.80% (target <= -2.0% for YES)
Gross Margin 96.50% (prev 32.44%; Δ 64.06pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 18.44% (prev 0.27%; Δ 18.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -136.5 (EBITDA TTM -220.8m / Interest Expense TTM 1.57m) >= 6 (WARN >= 3)

Altman Z'' -5.81

(A) 0.77 = (Total Current Assets 620.7m - Total Current Liabilities 121.3m) / Total Assets 649.4m
(B) -1.68 = Retained Earnings (Balance) -1.09b / Total Assets 649.4m
warn (B) unusual magnitude: -1.68 — check mapping/units
(C) -0.38 = EBIT TTM -214.2m / Avg Total Assets 564.1m
(D) -2.68 = Book Value of Equity -1.09b / Total Liabilities 406.8m
Total Rating: -5.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.24

1. Piotroski 3.0pt
2. FCF Yield 33.91%
3. FCF Margin 79.89%
4. Debt/Equity 0.08
5. Debt/Ebitda 0.34
6. ROIC - WACC (= -58.88)%
7. RoE -65.42%
8. Rev. Trend 74.28%
9. EPS Trend 5.19%

What is the price of KURA shares?

As of January 19, 2026, the stock is trading at USD 8.46 with a total of 2,301,485 shares traded.
Over the past week, the price has changed by -7.74%, over one month by -14.11%, over three months by -15.32% and over the past year by +14.48%.

Is KURA a buy, sell or hold?

Kura Oncology has received a consensus analysts rating of 4.53. Therefore, it is recommended to buy KURA.
  • Strong Buy: 10
  • Buy: 3
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the KURA price?

Issuer Target Up/Down from current
Wallstreet Target Price 32.6 284.8%
Analysts Target Price 32.6 284.8%
ValueRay Target Price 8 -5.6%

KURA Fundamental Data Overview January 17, 2026

P/S = 7.453
P/B = 3.1967
Revenue TTM = 104.0m USD
EBIT TTM = -214.2m USD
EBITDA TTM = -220.8m USD
Long Term Debt = 5.34m USD (from longTermDebt, last quarter)
Short Term Debt = 5.77m USD (from shortTermDebt, last quarter)
Debt = 19.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -75.8m USD (from netDebt column, last quarter)
Enterprise Value = 245.1m USD (775.3m + Debt 19.5m - CCE 549.7m)
Interest Coverage Ratio = -136.5 (Ebit TTM -214.2m / Interest Expense TTM 1.57m)
EV/FCF = 2.95x (Enterprise Value 245.1m / FCF TTM 83.1m)
FCF Yield = 33.91% (FCF TTM 83.1m / Enterprise Value 245.1m)
FCF Margin = 79.89% (FCF TTM 83.1m / Revenue TTM 104.0m)
Net Margin = -208.5% (Net Income TTM -216.9m / Revenue TTM 104.0m)
Gross Margin = 96.50% ((Revenue TTM 104.0m - Cost of Revenue TTM 3.64m) / Revenue TTM)
Gross Margin QoQ = 84.52% (prev 98.53%)
Tobins Q-Ratio = 0.38 (Enterprise Value 245.1m / Total Assets 649.4m)
Interest Expense / Debt = 2.02% (Interest Expense 393.0k / Debt 19.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -169.2m (EBIT -214.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.12 (Total Current Assets 620.7m / Total Current Liabilities 121.3m)
Debt / Equity = 0.08 (Debt 19.5m / totalStockholderEquity, last quarter 242.5m)
Debt / EBITDA = 0.34 (negative EBITDA) (Net Debt -75.8m / EBITDA -220.8m)
Debt / FCF = -0.91 (Net Debt -75.8m / FCF TTM 83.1m)
Total Stockholder Equity = 331.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.45% (Net Income -216.9m / Total Assets 649.4m)
RoE = -65.42% (Net Income TTM -216.9m / Total Stockholder Equity 331.5m)
RoCE = -63.60% (EBIT -214.2m / Capital Employed (Equity 331.5m + L.T.Debt 5.34m))
RoIC = -49.61% (negative operating profit) (NOPAT -169.2m / Invested Capital 341.1m)
WACC = 9.27% (E(775.3m)/V(794.8m) * Re(9.46%) + D(19.5m)/V(794.8m) * Rd(2.02%) * (1-Tc(0.21)))
Discount Rate = 9.46% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.46%
[DCF Debug] Terminal Value 74.30% ; FCFF base≈83.1m ; Y1≈86.7m ; Y5≈100.0m
Fair Price DCF = 16.92 (EV 1.40b - Net Debt -75.8m = Equity 1.47b / Shares 87.0m; r=9.27% [WACC]; 5y FCF grow 4.64% → 2.90% )
EPS Correlation: 5.19 | EPS CAGR: 23.20% | SUE: 1.21 | # QB: 1
Revenue Correlation: 74.28 | Revenue CAGR: 52.37% | SUE: -1.39 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.89 | Chg30d=-0.098 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=-2.60 | Chg30d=-0.331 | Revisions Net=-2 | Growth EPS=-4.7% | Growth Revenue=+54.8%

Additional Sources for KURA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle